1
|
Kang JY, Kim S, Kim J, Kang NG, Yang CS, Min SJ, Kim JW. Cell-penetrating peptide-conjugated lipid/polymer hybrid nanovesicles for endoplasmic reticulum-targeting intracellular delivery. J Mater Chem B 2021; 9:464-470. [DOI: 10.1039/d0tb01940b] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
An ER-targeting, intracellular delivery approach that utilizes cell-penetrating peptide-conjugated lipid/polymer hybrid nanovehicles is proposed.
Collapse
Affiliation(s)
- Jeong Yi Kang
- School of Chemical Engineering
- Sungkyunkwan University
- Suwon 16419
- Republic of Korea
| | - Seulgi Kim
- School of Chemical Engineering
- Sungkyunkwan University
- Suwon 16419
- Republic of Korea
| | - Juhyeon Kim
- Department of Chemistry
- Korea University
- Seoul 02841
- Republic of Korea
| | - Nae-Gyu Kang
- R&D Campus
- LG Household & Health Care
- Seoul 07795
- Republic of Korea
| | - Chul-Su Yang
- Department of Molecular & Life Science
- Hanyang University
- Ansan 15588
- Republic of Korea
| | - Sun-Joon Min
- Department of Chemical & Molecular Engineering/Applied Chemistry, Center for Bionano Intelligence Education and Research
- Hanyang University
- Ansan 15588
- Republic of Korea
| | - Jin Woong Kim
- School of Chemical Engineering
- Sungkyunkwan University
- Suwon 16419
- Republic of Korea
| |
Collapse
|
2
|
Sharma P, Roberts C, Herpai D, Fokt ID, Priebe W, Debinski W. Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals (Basel) 2020; 13:E77. [PMID: 32340173 PMCID: PMC7243104 DOI: 10.3390/ph13040077] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Revised: 04/14/2020] [Accepted: 04/15/2020] [Indexed: 12/11/2022] Open
Abstract
Glioblastoma (GBM) is a complex and heterogeneous tumor that warrants a comprehensive therapeutic approach for treatment. Tumor-associated antigens offer an opportunity to selectively target various components of the GBM microenvironment while sparing the normal cells within the central nervous system. In this study, we conjugated a multivalent vector protein, QUAD 3.0, that can target four receptors: EphA3, EphA2, EphB2, and also IL-13RA2, spanning virtually 100% of the GBM microenvironment, to doxorubicin derivatives. The conjugates effectively bound to all four receptors, although to varying degrees, and delivered cytotoxic loads to both established and patient-derived GBM cell lines, with IC50 values in the low nM range. The conjugates were also non-toxic to animals. We anticipate that the QUAD 3.0 Dox conjugates will be further used in preclinical models and possibly clinics in the foreseeable future.
Collapse
Affiliation(s)
- Puja Sharma
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC 27157, USA; (P.S.); (C.R.); (D.H.)
| | - Callie Roberts
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC 27157, USA; (P.S.); (C.R.); (D.H.)
| | - Denise Herpai
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC 27157, USA; (P.S.); (C.R.); (D.H.)
| | - Izabela D. Fokt
- Department of Experimental Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77054, USA; (I.D.F.); (W.P.)
| | - Waldemar Priebe
- Department of Experimental Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77054, USA; (I.D.F.); (W.P.)
| | - Waldemar Debinski
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC 27157, USA; (P.S.); (C.R.); (D.H.)
| |
Collapse
|
3
|
Sharma P, Sonawane P, Herpai D, D’Agostino R, Rossmeisl J, Tatter S, Debinski W. Multireceptor targeting of glioblastoma. Neurooncol Adv 2020; 2:vdaa107. [PMID: 33150335 PMCID: PMC7596893 DOI: 10.1093/noajnl/vdaa107] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Treatment for glioblastoma (GBM) remains an unmet need in medicine. Novel therapies that address GBM complexity and heterogeneity in particular are warranted. To this end, we target 4 tumor-associated receptors at a time that span virtually all of the GBM microenvironment including bulk tumor cells, infiltrating tumor cells, neovasculature, and tumor-infiltrating cells with one pharmaceutical agent delivering a cytotoxic load. METHODS We engineered multivalent ligand-based vector proteins termed QUAD with an ability to bind to 4 of the following GBM-associated receptors: IL-13RA2, EphA2, EphA3, and EphB2. We conjugated QUAD with a modified bacterial toxin PE38QQR and tested it in vitro and in vivo. RESULTS The QUAD variants preserved functional characteristics of the respective ligands for the 4 receptors. The QUAD 3.0 variant conjugate was highly cytotoxic to GBM cells, but it was nontoxic in mice, and the conjugate exhibited strong antitumor effect in a dog with spontaneous GBM. CONCLUSION The QUAD addresses, to a large extent, the issues of intra- and intertumoral heterogeneity and, at the same time, it targets several pathophysiologically important tumor compartments in GBM through multiple receptors overexpressed in tumors allowing for what we call "molecular resection." QUAD-based targeted agents warrant further pre- and clinical development.
Collapse
Affiliation(s)
- Puja Sharma
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA
| | - Poonam Sonawane
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA
- Children’s Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA
| | - Denise Herpai
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA
| | - Ralph D’Agostino
- Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
| | - John Rossmeisl
- Neurology and Neurosurgery, Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, USA
| | - Stephen Tatter
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA
- Department of Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA
| | - Waldemar Debinski
- Brain Tumor Center of Excellence, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, North Carolina, USA
| |
Collapse
|
4
|
Louzoun‐Zada S, Jaber QZ, Fridman M. Guiding Drugs to Target‐Harboring Organelles: Stretching Drug‐Delivery to a Higher Level of Resolution. Angew Chem Int Ed Engl 2019. [DOI: 10.1002/ange.201906284] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Sivan Louzoun‐Zada
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences Tel Aviv University Tel Aviv 6997801 Israel
| | - Qais Z. Jaber
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences Tel Aviv University Tel Aviv 6997801 Israel
| | - Micha Fridman
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences Tel Aviv University Tel Aviv 6997801 Israel
| |
Collapse
|
5
|
Louzoun-Zada S, Jaber QZ, Fridman M. Guiding Drugs to Target-Harboring Organelles: Stretching Drug-Delivery to a Higher Level of Resolution. Angew Chem Int Ed Engl 2019; 58:15584-15594. [PMID: 31237741 DOI: 10.1002/anie.201906284] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Indexed: 01/04/2023]
Abstract
The ratio between the dose of drug required for optimal efficacy and the dose that causes toxicity is referred to as the therapeutic window. This ratio can be increased by directing the drug to the diseased tissue or pathogenic cell. For drugs targeting fungi and malignant cells, the therapeutic window can be further improved by increasing the resolution of drug delivery to the specific organelle that harbors the drug's target. Organelle targeting is challenging and is, therefore, an under-exploited strategy. Here we provide an overview of recent advances in control of the subcellular distribution of small molecules with the focus on chemical modifications. Highlighted are recent examples of active and passive organelle-specific targeting by incorporation of organelle-directing molecular determinants or by chemical modifications of the pharmacophore. The outstanding potential that lies in the development of organelle-specific drugs is becoming increasingly apparent.
Collapse
Affiliation(s)
- Sivan Louzoun-Zada
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - Qais Z Jaber
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel
| | - Micha Fridman
- School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv, 6997801, Israel
| |
Collapse
|
6
|
Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci 2018; 19:E3326. [PMID: 30366424 PMCID: PMC6274942 DOI: 10.3390/ijms19113326] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2018] [Revised: 10/16/2018] [Accepted: 10/19/2018] [Indexed: 12/24/2022] Open
Abstract
Among primary brain tumors, malignant gliomas are notably difficult to manage. The higher-grade tumors represent an unmet need in medicine. There have been extensive efforts to implement receptor-targeted therapeutic approaches directed against gliomas. These approaches include immunotherapies, such as vaccines, adoptive immunotherapy, and passive immunotherapy. Targeted cytotoxic radio energy and pro-drug activation have been designed specifically for brain tumors. The field of targeting through receptors progressed significantly with the discovery of an interleukin 13 receptor alpha 2 (IL-13RA2) as a tumor-associated receptor over-expressed in most patients with glioblastoma (GBM) but not in normal brain. IL-13RA2 has been exploited in novel experimental therapies with very encouraging clinical responses. Other receptors are specifically over-expressed in many patients with GBM, such as EphA2 and EphA3 receptors, among others. These findings are important in view of the heterogeneity of GBM tumors and multiple tumor compartments responsible for tumor progression and resistance to therapies. The combined targeting of multiple receptors in different tumor compartments should be a preferred way to design novel receptor-targeted therapeutic approaches in gliomas.
Collapse
Affiliation(s)
- Puja Sharma
- Brain Tumor Center of Excellence, Department of Cancer Biology, Wake Forest University School of Medicine, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA.
| | - Waldemar Debinski
- Brain Tumor Center of Excellence, Department of Cancer Biology, Wake Forest University School of Medicine, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, 1 Medical Center Boulevard, Winston-Salem, NC 27157, USA.
| |
Collapse
|
7
|
Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer 2018; 6:78. [PMID: 30081947 PMCID: PMC6091193 DOI: 10.1186/s40425-018-0381-3] [Citation(s) in RCA: 92] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Accepted: 06/27/2018] [Indexed: 12/13/2022] Open
Abstract
In this White Paper, we discuss the current state of microbial cancer therapy. This paper resulted from a meeting ('Microbial Based Cancer Therapy') at the US National Cancer Institute in the summer of 2017. Here, we define 'Microbial Therapy' to include both oncolytic viral therapy and bacterial anticancer therapy. Both of these fields exploit tumor-specific infectious microbes to treat cancer, have similar mechanisms of action, and are facing similar challenges to commercialization. We designed this paper to nucleate this growing field of microbial therapeutics and increase interactions between researchers in it and related fields. The authors of this paper include many primary researchers in this field. In this paper, we discuss the potential, status and opportunities for microbial therapy as well as strategies attempted to date and important questions that need to be addressed. The main areas that we think will have the greatest impact are immune stimulation, control of efficacy, control of delivery, and safety. There is much excitement about the potential of this field to treat currently intractable cancer. Much of the potential exists because these therapies utilize unique mechanisms of action, difficult to achieve with other biological or small molecule drugs. By better understanding and controlling these mechanisms, we will create new therapies that will become integral components of cancer care.
Collapse
Affiliation(s)
- Neil S Forbes
- grid.266683.f0000 0001 2184 9220Department of Chemical EngineeringUniversity of Massachusetts 159 Goessmann Hall 01003 Amherst MA USA
| | | | - Liang Deng
- 0000 0001 2171 9952grid.51462.34Department of Medicine, Memorial Sloan Kettering Cancer Center 10065 New York NY USA
| | - Laura Evgin
- 0000 0004 0459 167Xgrid.66875.3aMayo Clinic Rochester USA
| | - Steve Fiering
- 0000 0001 2179 2404grid.254880.3Geisel School of Medicine at Dartmouth Hanover USA
| | | | - Claudia Gravekamp
- 0000000121791997grid.251993.5Albert Einstein College of Medicine Bronx USA
| | - James L Gulley
- 0000 0004 1936 8075grid.48336.3aNational Cancer Institute, National Institutes of Health Bethesda USA
| | | | - Robert M Hoffman
- 0000 0001 2107 4242grid.266100.3UC, San Diego San Diego USA
- 0000 0004 0461 1271grid.417448.aAntiCancer Inc. San Diego USA
| | - Balveen Kaur
- 0000000121548364grid.55460.32University of Texas Austin USA
| | - Ke Liu
- 0000 0001 2243 3366grid.417587.8Center for Biologics Evaluation and ResearchUS Food and Drug Administration Silver Spring USA
| | | | - Ariel E Marciscano
- 0000 0004 1936 8075grid.48336.3aNational Cancer Institute, National Institutes of Health Bethesda USA
| | | | - Sheryl Ruppel
- 0000 0004 4665 8158grid.419407.fLeidos Biomedical Research, Inc. Frederick USA
| | - Daniel A Saltzman
- 0000000419368657grid.17635.36University of Minnesota Minneapolis USA
| | | | - Steve Thorne
- 0000 0004 1936 9000grid.21925.3dUniversity of Pittsburgh Pittsburgh USA
| | - Richard G Vile
- 0000 0004 0459 167Xgrid.66875.3aMayo Clinic Rochester USA
| | | | - Shibin Zhou
- 0000 0001 2171 9311grid.21107.35Johns Hopkins University Baltimore USA
| | - Grant McFadden
- 0000 0001 2151 2636grid.215654.1Center for Immunotherapy, Vaccines and Virotherapy , Biodesign InstituteArizona State University 727 E Tyler Street, Room A330E 85281 Tempe AZ USA
| |
Collapse
|
8
|
Sarafian VS, Koev I, Mehterov N, Kazakova M, Dangalov K. LAMP-1 gene is overexpressed in high grade glioma. APMIS 2018; 126:657-662. [PMID: 29920782 DOI: 10.1111/apm.12856] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 05/03/2018] [Indexed: 12/13/2022]
Abstract
High-grade gliomas (HGG) are the most frequent brain tumors in adults. Glioblastoma multiforme (GBM) is their most aggressive form resistant to therapy. It was shown that inhibition of autophagy reduced GBM development and autophagy interfering agents are regarded as a new strategy to fight glioma cells. The lysosome-associated membrane proteins (LAMPs) display differential expression particularly in cancer. There are few data on their expression and especially on their molecular profile. The aim of the present study is to investigate the expression of LAMP-1 and LAMP-2 genes and proteins in HGG. Newly diagnosed patients with HGG and healthy controls were examined by immunohistochemistry and qPCR for both protein and mRNA levels of LAMP-1 and LAMP-2. The transcriptional activity of LAMP-1 in HGG was significantly higher compared to normal brain and to LAMP-2. The two glycoproteins were detected in the cytosol of tumor cells with varying intensity, LAMP-1 showing again enhanced expression. In conclusion, novel data on LAMP-1 overexpression in HGG are presented suggesting involvement of this gene and protein in cell adhesion and tumor progression. These findings might help the elucidation of the complex biological role of the multifunctional LAMPs proteins and to predict novel therapeutic targets in lysosomes.
Collapse
Affiliation(s)
- Victoria S Sarafian
- Department of Medical Biology, Medical Faculty, Medical University, Plovdiv, Bulgaria
- Technological Center for Emergency Medicine, Plovdiv, Bulgaria
| | - Ilian Koev
- Department of Neurosurgery, St. George University Hospital, Plovdiv, Bulgaria
- University Hospital Pulmed, Plovdiv, Bulgaria
| | - Nikolay Mehterov
- Department of Medical Biology, Medical Faculty, Medical University, Plovdiv, Bulgaria
- Technological Center for Emergency Medicine, Plovdiv, Bulgaria
| | - Maria Kazakova
- Department of Medical Biology, Medical Faculty, Medical University, Plovdiv, Bulgaria
| | - Krassimir Dangalov
- Department of General and Clinical Pathology, Medical Faculty, Medical University, Plovdiv, Bulgaria
| |
Collapse
|
9
|
Affiliation(s)
- Waldemar Debinski
- Brain Tumor Center of Excellence, Thomas K Hearn, Jr. Brain Tumor Research Center.,Department of Cancer Biology, Radiation Oncology Microbiology and Immunology, and Translational Science Institute, Wake Forest Baptist Medical Center Comprehensive Cancer Center, Winston-Salem, NC, USA
| |
Collapse
|